Motif Bio Plc (LON:MTFB) – is the topic of discussion when Vadim Alexandre of Northland Capital caught up with DirectorsTalk. Vadim discusses the new trial supplies milestone reached and the
Northland Capital partners view on Motif Bio PLC: The reprocessing of this acquired API will save Motif considerable time and money, representing an important milestone for the business. As such,
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today told DirectorsTalk that clinical trial supplies in the form of sterile ampoules of iclaprim
Graham Lumsden, Chief Executive Officer at Motif, said: “Being selected to present at such an important event is recognition of Motif’s success to date and future potential. Members of the
Motif Bio’s Dr. Graham Lumsden discusses the fixed 80mg dose for the Iclaprim Phase III clinical trials in this exclusive interview with DirectorsTalk
Motif Bio Plc (LON:MTFB) CEO Dr. Graham Lumsden chats to DirectorsTalk about the Phase III Clinical Trials 80mg fixed dose. Graham explains why a fixed dose is important, how this
Northland Capital partners view on MotifBio PLC: This fixed dose regime is important for the iclaprim Phase 3 trials, in that it optimises pharmacodynamic parameters associated with antibacterial efficacy, while
Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk today that it has received written concurrence from the United States Food and Drug
Motif Bio Plc (LON:MTFB) a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life threatening infections caused by multi-drug resistant bacteria,
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, yesterday announced that it has received written advice from a Scientific Advice Meeting with the Medicines Evaluation
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
